UK markets close in 3 hours 52 minutes
  • FTSE 100

    7,508.73
    -27.33 (-0.36%)
     
  • FTSE 250

    20,196.06
    -140.35 (-0.69%)
     
  • AIM

    927.13
    -4.41 (-0.47%)
     
  • GBP/EUR

    1.1877
    -0.0012 (-0.10%)
     
  • GBP/USD

    1.2067
    -0.0028 (-0.23%)
     
  • BTC-GBP

    19,698.56
    -323.81 (-1.62%)
     
  • CMC Crypto 200

    566.38
    -5.53 (-0.97%)
     
  • S&P 500

    4,305.20
    +8.06 (+0.19%)
     
  • DOW

    34,152.01
    +239.61 (+0.71%)
     
  • CRUDE OIL

    86.39
    -0.14 (-0.16%)
     
  • GOLD FUTURES

    1,782.40
    -7.30 (-0.41%)
     
  • NIKKEI 225

    29,222.77
    +353.86 (+1.23%)
     
  • HANG SENG

    19,922.45
    +91.93 (+0.46%)
     
  • DAX

    13,756.29
    -153.83 (-1.11%)
     
  • CAC 40

    6,558.16
    -34.42 (-0.52%)
     

NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS, June 09, 2022--(BUSINESS WIRE)--Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date

Number of Shares
Outstanding

Total number of voting rights

Total voting rights,
gross (1)

Total voting rights,
net (2)

May 31, 2022

34,875,872

36,393,442

36,373,830

(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(2) The total number of net (or "exercisable at a Shareholders’ Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005920/en/

Contacts

Nanobiotix

Nanobiotix Communications
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Nanobiotix Investor Relations
Kate McNeil
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com

Media Relations

France – Ulysse Communication
Pierre-Louis Germain
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com

US – Porter Novelli
Caitlin Hunt
+1 (781) 985-5967
Caitlin.hunt@porternovelli.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting